Stocks rise as investors cheered strong quarterly numbers from companies like Coca-Cola and United Technologies.US Marketsread more
The IMF trims its economic growth forecast again as the U.S.-China trade war continues, Brexit worries linger and inflation remains muted.Economyread more
Citigroup thinks Tesla investors hoping for a post-earnings rally later this week should scrutinize a pair of related financial metrics.Investingread more
Olive branches were extended from both China and the U.S. as the two nations are set to restart face-to-face trade negotiations after a month-long truce.Marketsread more
In advance of Amazon's earnings report on Thursday, Craig Johnson says the stock chart is pointing to big gains. Mark Tepper also likes the stock.Trading Nationread more
Coca-Cola topped Wall Street's expectations for earnings and revenue.Food & Beverageread more
New disclosures show Facebook and Amazon each spent more than $4 million on lobbying activity in the second quarter of 2019.Technologyread more
Boris Johnson, one of the biggest voices in the Brexit movement, wins the Conservative Party leadership race by a 2-1 margin.Europe Politicsread more
Disney can nearly double its earnings by 2024, Morgan Stanley said in a note to clients on Tuesday.Investingread more
Amazon is expected to report its second-quarter earnings on Thursday.Investingread more
The largest residential brokerage company in the U.S. is partnering with the largest online retailer in a strategy to boost sales for both.Real Estateread more
2016 has been most unkind to big bankers; no matter where they work, chances are their company's stock is down for the year.
Now Washington regulators are rubbing a little salt into the wound. The Department of Justice filed antitrust lawsuits that may result in the blocking of not one, but two proposed mega-healthcare mergers — Anthem-Cigna and Aetna-Humana — and should those combinations be killed, that would mean that the global volume of blocked mergers and acquisitions is about to hit an all-time high.
Not counting those healthcare transactions, there have been 590 mergers withdrawn globally so far through July 20, totaling more than $633 billion, according to Dealogic, a firm that tracks M&A stats. Add in the value of the Anthem-Cigna and Aetna-Humana deals ($54 billion and $34 billion, respectively), and that number shoots to more than $700 billion, the highest year-to-date total on record. Dealogic stats track back to 1995, but it's unlikely that there ever was a year where more M&A was killed.
On top of that, earlier this year Williams Companies' $55 billion sale to Energy Transfer Equity LP was scotched after an extended Securities and Exchange Commission review, due to tax issues.
The full-year record tally for busted deals has not yet been met: that came in 2007, when more than $1.12 trillion in M&A was withdrawn globally — but that year was more about market turmoil killing deal financing packages, than regulators swatting transactions down. But at this point the all-time record is well within striking distance.
Both deals' being targeted by the Justice Department for rejection surprised some on Wall Street. Thursday morning, the DOJ delivered and filed lawsuits against both deals. Attorney General Loretta Lynch announced the lawsuits in a press conference Thursday.
"These mergers would fundamentally reshape the health insurance industry," Lynch said. "They would leave much of the multi-trillion dollar health insurance industry in the hands of three mammoth insurance companies, restricting competition in key markets."
Once the DOJ files a lawsuit to block a deal, it's very likely that transaction will be scuttled, one way or another.
The two health giants said Thursday that they plan to "vigorously defend the companies' pending merger."
The Aetna-Humana deal was expected to be the easier of the two to win approval, as the only major overlap between the two companies was in their Medicare Advantage and Medicare Part D businesses. Aetna was willing to divest assets, but the expectation is that DOJ said the divestitures wouldn't alleviate the concern regarding competition in the area.
"The process to review Aetna-Humana is simple when compared to Anthem-Cigna, " Stifel analyst Thomas Carroll told CNBC earlier this month, explaining that their one area of overlap is Medicare. "It's primarily one product — Medicare Advantage and Medicare Part D. Market share data is readily available, so it should be much more objective."
— CNBC's Bertha Coombs and Christina Cheddar-Berk contributed to this report.